Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central nervous method, conolidine modulates alternate molecular targets. A Science Advances review observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which re